Contact information
Research groups
Colleges
Websites
-
Primary Care Clinical Trials Unit (CTU)
Research Group
-
Interdisciplinary Research in Health Sciences (IRIHS)
Research Group
Mona Koshkouei
DPhil (Oxon) | MPharm | MRPharmS | FHEA
Principal Pharmacist | Head of GMP Operations
My research interests are the impact on healthcare professionals' working practices as a result of regulation reform and digital systems integration with a specific interest in implementation of digital systems in healthcare. My work has focused on evaluating the challenges implicated in the scale-up and sustainability of the proposed technology, with community pharmacy implementation of the Falsified Medicines Directive as a case study.
I am a qualified pharmacist having specialised in clinical governance and pharmacy ethics & practice, and am engaged with teaching in this field alongside digital system implementation and health policy more broadly on a number of the department's courses and supervise Master's level projects. My career has been dedicated to designing and developing healthcare services across a wide range of clinical settings in addition to clinical training frameworks for hospital pharmacy.
My role in the PC-CTU is as Principal Pharmacist and Head of Good Manufacturing Practice (GMP) Operations for our clinical trials involving Investigational Medicinal Products (IMPs). I originally joined the PC-CTU in May 2020 as the pharmacist on the PRINCIPLE trial, a UK-wide clinical study to find COVID-19 treatments for recovery at home. I now work across a number of clinical trials and studies within the department.
Twitter: @MonaKoshkouei
Recent publications
-
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Journal article
Hobbs FR. et al, (2024), Journal of Infection, 89
-
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Journal article
Hayward G. et al, (2024), Journal of Infection, 88
-
Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Journal article
Gbinigie O. et al, (2023), BMJ Open, 13
-
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Journal article
Dorward J. et al, (2022), British Journal of General Practice, 72, E446 - E455
-
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Journal article
Yu LM. et al, (2021), The Lancet, 398, 843 - 855